Human testing

Primary human skin irritation of tetradecanol, hexadecanol, and octadecanol is nil they have been used for many years ia cosmetic creams and ointments (24). Based on human testing and iudustrial experience, the linear, even carbon number alcohols of 6—18 carbon atoms are not human skin sensitizers, nor are the 7-, 9- and 11-carbon alcohols and 2-ethylhexanol. Neither has iudustrial handling of other branched alcohols led to skin problems. Inhalation hazard, further mitigated by the low vapor pressure of these alcohols, is slight. Sustained breathing of alcohol vapor or mist should be avoided, however, as aspiration hazards have been reported (25). 

Apphcation for discovery and product patents must be made early in the process. Appropriate labels ate designed and the product is submitted to the FDA for approval to begin human testing in the form of an Investigational New Dmg Apphcation (INDA). When such approval is granted, the clinical evaluation is developed as follows. 

Skin tolerance was tested on rabbits. A 1 % alkanesulfonate solution applied five times did not produce any irritation on the rabbits skin. The same results were obtained by the closed patch test carried out with human test subjects in a hospital. The good dermatological properties were also confirmed by the Polano test (arm immersion test). 

Organophosphate Ester Hydraulic Fluids. Repeated application of a patch treated with 0.2 pL of Skydrol 500B-4 for 5 weeks (3 times/week) resulted in mild cumulative erythema confined to the contact site in 14 of 53 human test subjects, beginning with the third dose during the first week. No evidence of immediate primary dermal irritation was observed (Monsanto 1980). 

To determine whether human testing for a new drug or new drug product is reasonable, it is first necessary to conduct preclinical studies and to submit the IND. The necessary information needed to prepare the IND is outlined in Table 1. The IND is to contain information on appropriate prior animal studies for safety evaluation, any available clinical data, adequate drug identification and manufacturing instructions, and a detailed outline of the proposed clinical study, routs of administration, approximate number of patients to be used, and an estimate of the length of treatment and an environmental impact statement. 

The clinical evaluation of a new drug is divided into three phases. The first phase of human testing considers what chemical actions a drug has, how it is... 

OTCs) are used as subjects in bioequivalency studies. Such persons, often, university students, have been regarded as human test tubes in whom bioequivalency is evaluated. However, with the emergence of a school of thought that believes that bioequivalency should be a clinical mirror for the behavior of the test and reference products, this situation may change. Pregnant and nursing females are normally excluded from all bioequivalency studies. 

IND Investigational New Drug application, filed with FDA after preclinical testing is complete asking for permission to proceed with human tests. 

FAO/WHO/UNICEF, Human Testing of Supplementary Food Mixtures," PAG guideline no. 7, 1970. 

Hours since last ejaculation (Jouannet et al. 1981) and testis size (Kim and Lee 1982 Harvey and May 1989) both show the expected positive relationships (Table 1). Chronic alcoholism has a major negative influence on semen quality (Gomathi et al. 1993), but small amounts of alcohol are associated with more sperm in masturbatory ejaculates (Gerhard et al. 1992), as in Table 1. Autopsy studies have shown that the number of sperm manufactured per day by human testes declines by about 5 million for every year of a man s life after the age of about 25 y (Neaves et al. 1984). The decline per insemination of about 13 million for each year of age found in the Manchester study matches this autopsy work well, being the decline expected if the interval between ejaculations were 2—3 days. 

In 1954, despite the establishment of a framework for human testing, there was still no provision for procuring enlisted volunteers. Local enlisted personnel and lab... 

Back to the future. The situation with regard to human testing today is vastly different. Considerations of human civil rights (some of them seeming to be included in the name of what some call political correctness ) now cause conscientious investigators to ask themselves many questions before submitting a proposal. 

Oxender, Dale L., and Leonard E. Post. Novel Therapeutics from Modem Biotechnology From Laboratory to Human Testing. Berlin Springer, 1999. 

Human test panel exposures to vapor levels ranging from 53 to 521mg/m resulted in eye and throat irritation in all those exposed. In a study of workers exposed to vapor over a period of 18 years at levels up to 100 ppm, there were complaints of severe discomfort from burning of the eyes, nose, and throat. Eye irritation did not occur at 25 ppm, but nose and throat irritation occurred in some at 10 ppm. 

A solution containing 0.5% phenylethanol and 0.9% sodium chloride caused a sensation of smarting in human test subjects when dropped in the eye. Application of a 1% solution to rabbit eyes caused irritation of the conjunctiva and transient clouding of corneal epithelium. 

The liquid on the skin of human test subjects was not irritating or sensitizing. ... 

In human tests, exposure to 880 ppm (4100mg/m ) for 15 minutes resulted in eye and throat irritation with olfactory fatigue. The chief effect of exposure to high levels of the vapor is reported to be CNS depression. However, in an accidental brief exposure of 19 workers from an overheated solvent tank, the chief effect was dyspnea, which lasted for several minutes after the exposure. Two of the workers were cyanotic with tremor and nausea, but these were of brief duration. The absence of CNS depression was noteworthy. 

Toxicity involves the effect of various materials on living objects including bacteria, plants, mice, fish, and humans. Tests to determine the toxicity of materials are typically done in a number of ways including inhalation, simple skin contact, and subcutaneous injection. 

Thalidomide Developed as a sedative in the early 1960s but found to cause a rare birth defect, phocomelia. In 1962 legislation was passed that new drugs must undergo sufficient animal and human testing prior to approval for use by the US FDA. 

---